Popular Weight Loss Drug may Cause Liver, Kidney Failure

by Sheela Philomena on  December 12, 2012 at 11:32 AM Drug News
RSS Email Print This Page Comment
Font : A-A+

Orlistat - popular weight loss drug inhibits a key enzyme that may lead to severe toxicity of internal organs such as the liver and kidney, says University of Rhode Island researcher.

The inhibition is irreversible and can be caused by a low level of the drug.
 Popular Weight Loss Drug may Cause Liver, Kidney Failure
Popular Weight Loss Drug may Cause Liver, Kidney Failure

Professor Bingfang Yan's study funded by the National Institutes of Health, also found that the drug alters efficacy of medicines, and particularly limits the effectiveness of some anti-cancer drugs.

Orlistat, which was originally approved by the FDA in 1999 as the prescription drug Exenical, was approved in 2007 as the over-the-counter medication Alli. It has been the most commonly used medicine to treat obesity for more than a decade, Yan said.

"Since it has been available over-the-counter, there has been a drastic increase of toxicity among patients using the drug. It has been linked to severe liver failure, acute pancreatic failure and acute renal (kidney) failure," Yan said.

Yan said orlistat works in the intestinal tract by preventing fat from being absorbed by the body. It is generally accepted that orlistat remains in the intestine and that the body does not absorb it.

"But orlistat is reportedly absorbed, and certainly internal organs such as the liver and kidney are exposed to this drug upon absorption," he said.

The study showed that the drug is a potent inhibitor of carboxylesterase-2, which is a major detoxification enzyme in the liver, kidney and gastrointestinal track.

"When the activity of this enzyme drop in those organs, toxicity increases or the efficacy of some drugs are altered," Yan said.

The enzyme is known to metabolize a wide range of medicines including aspirin and the cancer drugs irinotecan and pentyl carbamate of p-aminobenzyl carbamate of doxazolidine.

"This study shows that orlistat profoundly alters the therapeutic potential of the anti-cancer drugs. In the case of the anti-cancer drugs, it weakens their effectiveness," Yan said.

Prior or co-presence of orlistat with one of the anti-cancer drugs resulted in cancer cells being far more prolific.

"Alli-based interactions can be key factors in the efficacy of medicines," Yan said.

Yan was also interested in Alli's effects on aspirin and its use as a blood thinner. "Aspirin is used to treat blood clots. Yan predicated: Orlistat would increase the therapeutic potential of aspirin, which may increase the tendency of bleeding."

Part of the research results will be published in the journal, Biochemical Pharmacology, which has the article posted on its website.

Source: ANI

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Diet Pills Drug Toxicity Obesity The Cabbage Diet Zone Diet Mediterranean Diet Bulimia Nervosa The Macrobiotic Diet Height and Weight-Kids Urinary Stones In Children 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive